Dana-Farber Cancer Institute, Philips partner to provide cancer decision support to physicians

Royal Philips will integrate clinical pathways from Boston-based Dana-Farber Cancer Institute into its Philips IntelliSpace Oncology Platform to provide physicians with clinical decision support related to cancer care management, the healthcare technology company announced May 31.

Dana-Farber Clinical Pathways provides physicians with best practices for cancer treatment from the medical center's oncologists. From within the Philips IntelliSpace Oncology Platform — a precision medicine tool that integrates radiology, pathology, genomics and EHR data — Dana-Farber Clinical Pathways will help physicians match cancer patients to appropriate treatment options.

Dana-Farber and Philips will update the clinical pathways several times a year to reflect changing cancer treatments and guidelines.

"Cancer medicine is changing rapidly, and physicians are tasked with interpreting massive amounts of new information generated from publications and clinical trials," Laurie H. Glimcher, MD, CEO of Dana-Farber, said in a May 31 statement. "Our clinical pathways provide physicians with the most current, evidence-based best practices so that all patients may be treated with the same high standard of care."

More articles on data analytics & precision medicine:
Cleveland Clinic to open 21k-square-foot biobank
Provider Data Action Alliance releases road map for trustworthy provider data
NIH seeks genome centers to sequence data from 200k 'All of Us' participants per year: 4 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers